🏛️ Verified NIH Record • Updated 2026-02-23
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant (NCT03850418)
🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Henry Ford Health System
🩺 Plain-English Summary (8th-Grade Level)
Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD
Who can join: Review the eligibility criteria below.
Location: Henry ford hospital — Detroit, Michigan
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Henry ford hospital — Detroit, Michigan
📞 Contact the Study Coordinator
Phone: (313) 916-5002
Email: SFARHAN1@HFHS.ORG
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myeloid Malignancy
- Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms — Boston, Massachusetts
- Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories — Rochester, New York
- Pre-myeloid Cancer and Bone Marrow Failure Clinic Study — Scottsdale, Arizona
- Germline Testing for Predisposition to Myeloid Malignancies — Boston, Massachusetts
- Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies — Birmingham, Alabama
- A Telehealth Advance Care Planning Intervention — Rochester, New York
Explore by condition: All Myeloid Malignancy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.